VERASTEM INC.
-
USD
(-)
- 15 min delayed data - NASDAQ Stocks
| Open: | - |
| Change: | - |
| Volume: | - |
| Low: | - |
| High: | - |
| High / Low range: | - |
| Type: | Stocks |
| Ticker: | VSTM |
| ISIN: |
VERASTEM INC. news, videos and press releases
For more news please use our advanced search feature.
VERASTEM INC. - More news...
VERASTEM INC. - More news...
- 04/07/2025 - 11:30 Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 03/25/2025 - 20:35 Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
- 03/20/2025 - 20:01 Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
- 02/20/2025 - 21:05 Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
- 01/29/2025 - 12:30 Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
- 01/23/2025 - 12:30 Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
- 01/15/2025 - 12:30 Verastem Oncology Names Matthew E. Ros as Chief Operating Officer
- 01/14/2025 - 12:30 Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China
- 01/13/2025 - 12:30 Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025
- 01/08/2025 - 12:30 Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 12/30/2024 - 21:30 Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
- 12/18/2024 - 12:30 Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
- 11/26/2024 - 12:00 Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference
- 07/10/2024 - 23:28 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
- 07/02/2024 - 14:15 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
- 06/24/2024 - 22:52 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
- 06/15/2024 - 12:15 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
- 05/30/2024 - 21:15 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
- 08/08/2023 - 20:05 Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
- 07/11/2023 - 11:00 Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer
- 07/10/2023 - 20:05 Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 07/05/2023 - 20:05 Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
- 06/16/2023 - 09:00 Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants
- 05/31/2023 - 13:11 Verastem Oncology Announces Reverse Stock Split
- 05/25/2023 - 21:05 Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib
- 05/16/2023 - 11:00 Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors
- 05/09/2023 - 20:05 Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
- 05/01/2023 - 11:00 Verastem Oncology to Participate in Upcoming Investor Conferences
- 04/26/2023 - 20:05 New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting
- 04/18/2023 - 11:05 Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days
